Kowalska, Magdalena published the artcileAntiepileptic drug tiagabine does not directly target key cardiac ion channels Kv11.1, Nav1.5 and Cav1.2, Recommanded Product: Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, the main research area is antiepileptic tiagabine target key ion channel Kv Nav Cav; ECG study; cardiac voltage-gated ion channels; molecular modeling; tiagabine.
Tiagabine is an antiepileptic drug used for the treatment of partial seizures in humans. Recently, this drug has been found useful in several non-epileptic conditions, including anxiety, chronic pain and sleep disorders. Since tachycardia-an impairment of cardiac rhythm due to cardiac ion channel dysfunction-is one of the most commonly reported non-neurol. adverse effects of this drug, in the present paper we have undertaken pharmacol. and numerical studies to assess a potential cardiovascular risk associated with the use of tiagabine. A chem. interaction of tiagabine with a model of human voltage-gated ion channels (VGICs) is described using the mol. docking method. The obtained in silico results imply that the adverse effects reported so far in the clin. cardiol. of tiagabine could not be directly attributed to its interactions with VGICs. This is also confirmed by the results from the isolated organ studies (i.e., calcium entry blocking properties test) and in vivo (ECG study) assays of the present research. It was found that tachycardia and other tiagabine-induced cardiac complications are not due to a direct effect of this drug on ventricular depolarization and repolarization.
Molecules published new progress about Anticonvulsants. 21829-25-4 belongs to class pyridine-derivatives, name is Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C17H18N2O6, Recommanded Product: Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate.